Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Detailed statistical analysis plan for the SafeBoosC III trial: a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hansen, ML, Pellicer, A, Gluud, C, Dempsey, E, Mintzer, J, Hyttel-Sorensen, S, Heuchan, AM, Hagmann, C, Dimitriou, G, Pichler, G, Naulaers, G, Cheng, G, Vilan, A, Tkaczyk, J, Kreutzer, KB, Fumagalli, M, Claris, O, Fredly, S, Szczapa, T, Lange, T, Jakobsen, JC & Greisen, G 2019, 'Detailed statistical analysis plan for the SafeBoosC III trial: a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants' Trials, vol. 20, no. 1, pp. 746. https://doi.org/10.1186/s13063-019-3756-y

APA

CBE

MLA

Vancouver

Author

Hansen, Mathias Lühr ; Pellicer, Adelina ; Gluud, Christian ; Dempsey, Eugene ; Mintzer, Jonathan ; Hyttel-Sorensen, Simon ; Heuchan, Anne Marie ; Hagmann, Cornelia ; Dimitriou, Gabriel ; Pichler, Gerhard ; Naulaers, Gunnar ; Cheng, Guoqiang ; Vilan, Ana ; Tkaczyk, Jakub ; Kreutzer, Karen B ; Fumagalli, Monica ; Claris, Olivier ; Fredly, Siv ; Szczapa, Tomasz ; Lange, Theis ; Jakobsen, Janus Christian ; Greisen, Gorm. / Detailed statistical analysis plan for the SafeBoosC III trial : a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants. In: Trials. 2019 ; Vol. 20, No. 1. pp. 746.

Bibtex

@article{a0f683b4f72d43488bf7acbcb99a2d14,
title = "Detailed statistical analysis plan for the SafeBoosC III trial: a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants",
abstract = "BACKGROUND: Infants born extremely preterm are at high risk of dying or suffering from severe brain injuries. Treatment guided by monitoring of cerebral oxygenation may reduce the risk of death and neurologic complications. The SafeBoosC III trial evaluates the effects of treatment guided by cerebral oxygenation monitoring versus treatment as usual. This article describes the detailed statistical analysis plan for the main publication, with the aim to prevent outcome reporting bias and data-driven analyses.METHODS/DESIGN: The SafeBoosC III trial is an investigator-initiated, randomised, multinational, pragmatic phase III trial with a parallel group structure, designed to investigate the benefits and harms of treatment based on cerebral near-infrared spectroscopy monitoring compared with treatment as usual. Randomisation will be 1:1 stratified for neonatal intensive care unit and gestational age (lower gestational age (< 26 weeks) compared to higher gestational age (≥ 26 weeks)). The primary outcome is a composite of death or severe brain injury at 36 weeks postmenstrual age. Primary analysis will be made on the intention-to-treat population for all outcomes, using mixed-model logistic regression adjusting for stratification variables. In the primary analysis, the twin intra-class correlation coefficient will not be considered. However, we will perform sensitivity analyses to address this. Our simulation study suggests that the inclusion of multiple births is unlikely to significantly affect our assessment of intervention effects, and therefore we have chosen the analysis where the twin intra-class correlation coefficient will not be considered as the primary analysis.DISCUSSION: In line with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines, we have developed and published this statistical analysis plan for the SafeBoosC III trial, prior to any data analysis.TRIAL REGISTRATION: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.",
author = "Hansen, {Mathias L{\"u}hr} and Adelina Pellicer and Christian Gluud and Eugene Dempsey and Jonathan Mintzer and Simon Hyttel-Sorensen and Heuchan, {Anne Marie} and Cornelia Hagmann and Gabriel Dimitriou and Gerhard Pichler and Gunnar Naulaers and Guoqiang Cheng and Ana Vilan and Jakub Tkaczyk and Kreutzer, {Karen B} and Monica Fumagalli and Olivier Claris and Siv Fredly and Tomasz Szczapa and Theis Lange and Jakobsen, {Janus Christian} and Gorm Greisen",
year = "2019",
month = "12",
day = "19",
doi = "10.1186/s13063-019-3756-y",
language = "English",
volume = "20",
pages = "746",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Detailed statistical analysis plan for the SafeBoosC III trial

T2 - a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants

AU - Hansen, Mathias Lühr

AU - Pellicer, Adelina

AU - Gluud, Christian

AU - Dempsey, Eugene

AU - Mintzer, Jonathan

AU - Hyttel-Sorensen, Simon

AU - Heuchan, Anne Marie

AU - Hagmann, Cornelia

AU - Dimitriou, Gabriel

AU - Pichler, Gerhard

AU - Naulaers, Gunnar

AU - Cheng, Guoqiang

AU - Vilan, Ana

AU - Tkaczyk, Jakub

AU - Kreutzer, Karen B

AU - Fumagalli, Monica

AU - Claris, Olivier

AU - Fredly, Siv

AU - Szczapa, Tomasz

AU - Lange, Theis

AU - Jakobsen, Janus Christian

AU - Greisen, Gorm

PY - 2019/12/19

Y1 - 2019/12/19

N2 - BACKGROUND: Infants born extremely preterm are at high risk of dying or suffering from severe brain injuries. Treatment guided by monitoring of cerebral oxygenation may reduce the risk of death and neurologic complications. The SafeBoosC III trial evaluates the effects of treatment guided by cerebral oxygenation monitoring versus treatment as usual. This article describes the detailed statistical analysis plan for the main publication, with the aim to prevent outcome reporting bias and data-driven analyses.METHODS/DESIGN: The SafeBoosC III trial is an investigator-initiated, randomised, multinational, pragmatic phase III trial with a parallel group structure, designed to investigate the benefits and harms of treatment based on cerebral near-infrared spectroscopy monitoring compared with treatment as usual. Randomisation will be 1:1 stratified for neonatal intensive care unit and gestational age (lower gestational age (< 26 weeks) compared to higher gestational age (≥ 26 weeks)). The primary outcome is a composite of death or severe brain injury at 36 weeks postmenstrual age. Primary analysis will be made on the intention-to-treat population for all outcomes, using mixed-model logistic regression adjusting for stratification variables. In the primary analysis, the twin intra-class correlation coefficient will not be considered. However, we will perform sensitivity analyses to address this. Our simulation study suggests that the inclusion of multiple births is unlikely to significantly affect our assessment of intervention effects, and therefore we have chosen the analysis where the twin intra-class correlation coefficient will not be considered as the primary analysis.DISCUSSION: In line with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines, we have developed and published this statistical analysis plan for the SafeBoosC III trial, prior to any data analysis.TRIAL REGISTRATION: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.

AB - BACKGROUND: Infants born extremely preterm are at high risk of dying or suffering from severe brain injuries. Treatment guided by monitoring of cerebral oxygenation may reduce the risk of death and neurologic complications. The SafeBoosC III trial evaluates the effects of treatment guided by cerebral oxygenation monitoring versus treatment as usual. This article describes the detailed statistical analysis plan for the main publication, with the aim to prevent outcome reporting bias and data-driven analyses.METHODS/DESIGN: The SafeBoosC III trial is an investigator-initiated, randomised, multinational, pragmatic phase III trial with a parallel group structure, designed to investigate the benefits and harms of treatment based on cerebral near-infrared spectroscopy monitoring compared with treatment as usual. Randomisation will be 1:1 stratified for neonatal intensive care unit and gestational age (lower gestational age (< 26 weeks) compared to higher gestational age (≥ 26 weeks)). The primary outcome is a composite of death or severe brain injury at 36 weeks postmenstrual age. Primary analysis will be made on the intention-to-treat population for all outcomes, using mixed-model logistic regression adjusting for stratification variables. In the primary analysis, the twin intra-class correlation coefficient will not be considered. However, we will perform sensitivity analyses to address this. Our simulation study suggests that the inclusion of multiple births is unlikely to significantly affect our assessment of intervention effects, and therefore we have chosen the analysis where the twin intra-class correlation coefficient will not be considered as the primary analysis.DISCUSSION: In line with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines, we have developed and published this statistical analysis plan for the SafeBoosC III trial, prior to any data analysis.TRIAL REGISTRATION: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.

U2 - 10.1186/s13063-019-3756-y

DO - 10.1186/s13063-019-3756-y

M3 - Journal article

VL - 20

SP - 746

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

ER -

ID: 58954032